^
    1m
    Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=25, Recruiting, M.D. Anderson Cancer Center | N=18 --> 25
    Enrollment change
    |
    cisplatin • Viracept (nelfinavir)
    2ms
    COAST Therapy in Advanced Solid Tumors and Prostate Cancer (clinicaltrials.gov)
    P1/2, N=76, Recruiting, Medical University of South Carolina | Trial completion date: Oct 2026 --> May 2027 | Trial primary completion date: Oct 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    dasatinib • sirolimus • metformin • hydroxychloroquine • Viracept (nelfinavir)
    2ms
    Autophagy Maintenance (AUTOMAIN) (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Medical University of South Carolina | Initiation date: Sep 2025 --> Jan 2026
    Trial initiation date
    |
    Avastin (bevacizumab) • hydroxychloroquine • Viracept (nelfinavir)
    2ms
    Nelfinavir triggers ferroptosis by inducing ER stress mediated downregulation of GPX4/GSH system, upregulation of NRF2/HO-1 axis, and mitochondrial impairment in hepatocellular carcinoma cells. (PubMed, Cell Death Discov)
    In a mouse model of HCC xenografts, nelfinavir treatment significantly suppressed tumor growth, and this effect was more pronounced when nelfinavir and sorafenib were administered together. Collectively, we demonstrate that nelfinavir can induce ferroptosis in an ER stress dependent manner, thereby identifying a new inducer of ferroptosis that can potentially be repurposed to treat HCC.
    Journal
    |
    HMOX1 (Heme Oxygenase 1) • GPX4 (Glutathione Peroxidase 4)
    |
    sorafenib • Viracept (nelfinavir)
    4ms
    NELCER: Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix (clinicaltrials.gov)
    P3, N=348, Active, not recruiting, Tata Memorial Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cisplatin • Viracept (nelfinavir) • ondansetron intravenous
    5ms
    Autophagy Maintenance (AUTOMAIN) (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Medical University of South Carolina | Initiation date: Jun 2025 --> Sep 2025
    Trial initiation date
    |
    Avastin (bevacizumab) • hydroxychloroquine • Viracept (nelfinavir)
    6ms
    Machine learning-based identification of exosome-related biomarkers and drugs prediction in nasopharyngeal carcinoma. (PubMed, Discov Oncol)
    This study identifies five exosome-related key genes, utilizing machine learning approaches to develop a diagnostic model and uncover potential drug targets for NPC. These findings offer novel perspectives for both the diagnosis and therapeutic development of NPC.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CCL2 (Chemokine (C-C motif) ligand 2) • LGALS3 (Galectin 3) • LGALS3BP (Lectin galactoside-binding soluble 3-binding protein)
    |
    Viracept (nelfinavir)
    7ms
    Autophagy Maintenance (AUTOMAIN) (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Medical University of South Carolina
    New P2 trial
    |
    Avastin (bevacizumab) • hydroxychloroquine • Viracept (nelfinavir)
    8ms
    KiBS: A Study of Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Reduction of Mother-to-child HIV Transmission During Breastfeeding (clinicaltrials.gov)
    P2, N=520, Completed, Centers for Disease Control and Prevention | Unknown status --> Completed
    Trial completion
    |
    CD4 (CD4 Molecule)
    |
    Viracept (nelfinavir)
    9ms
    Harnessing p53 for targeted cancer therapy: new advances and future directions. (PubMed, Transcription)
    Two main types of drugs have emerged among compounds used in the following combination treatments: first, modulators of the p53-regulated transcriptome (including chromatin modifiers), translatome, and proteome, and second, drugs targeting the downstream pathways such as apoptosis, cell cycle arrest, DNA repair, metabolic stress response, immune response, ferroptosis, and growth factor signaling. Here, we review the current literature in this field, while also highlighting overarching principles that could guide target selection in future combination treatments.
    Review • Journal
    |
    TP53 (Tumor protein P53)
    |
    Viracept (nelfinavir)
    10ms
    COAST Therapy in Advanced Solid Tumors and Prostate Cancer (clinicaltrials.gov)
    P1/2, N=76, Recruiting, Medical University of South Carolina | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    dasatinib • sirolimus • metformin • hydroxychloroquine • Viracept (nelfinavir)
    1year
    ARTISTRY-1: Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (clinicaltrials.gov)
    P2/3, N=689, Active, not recruiting, Gilead Sciences | Recruiting --> Active, not recruiting | Trial completion date: Nov 2028 --> Jul 2028 | Trial primary completion date: Jan 2026 --> Sep 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Viracept (nelfinavir)